SE0301109D0 - Nucleotide vaccine composition - Google Patents

Nucleotide vaccine composition

Info

Publication number
SE0301109D0
SE0301109D0 SE0301109A SE0301109A SE0301109D0 SE 0301109 D0 SE0301109 D0 SE 0301109D0 SE 0301109 A SE0301109 A SE 0301109A SE 0301109 A SE0301109 A SE 0301109A SE 0301109 D0 SE0301109 D0 SE 0301109D0
Authority
SE
Sweden
Prior art keywords
component
dendritic cells
bcr
positive tumor
plasmacytoid dendritic
Prior art date
Application number
SE0301109A
Other languages
English (en)
Swedish (sv)
Inventor
Mallen Huang
Original Assignee
Mallen Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallen Huang filed Critical Mallen Huang
Priority to SE0301109A priority Critical patent/SE0301109D0/xx
Publication of SE0301109D0 publication Critical patent/SE0301109D0/xx
Priority to EP04727465A priority patent/EP1658097B1/de
Priority to CA002522456A priority patent/CA2522456A1/en
Priority to CN2004800164612A priority patent/CN1805758B/zh
Priority to US10/551,804 priority patent/US10799553B2/en
Priority to JP2006508023A priority patent/JP2006523688A/ja
Priority to AU2004227821A priority patent/AU2004227821A1/en
Priority to AT04727465T priority patent/ATE514433T1/de
Priority to PCT/SE2004/000589 priority patent/WO2004089413A1/en
Priority to US16/985,393 priority patent/US11298398B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE0301109A 2003-04-14 2003-04-14 Nucleotide vaccine composition SE0301109D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition
EP04727465A EP1658097B1 (de) 2003-04-14 2004-04-14 Nucleotid und zelluläre vakzine-zusammensetzung
CA002522456A CA2522456A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
CN2004800164612A CN1805758B (zh) 2003-04-14 2004-04-14 核酸和细胞疫苗的组分
US10/551,804 US10799553B2 (en) 2003-04-14 2004-04-14 Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells
JP2006508023A JP2006523688A (ja) 2003-04-14 2004-04-14 ヌクレオチド・ワクチン組成、ヌクレオチド及び細胞ワクチン組成の産出方法、ワクチン組成、ワクチン組成使用、免疫反応産出方法、疾患の治療または予防方法、抗原提示細胞から成るキット
AU2004227821A AU2004227821A1 (en) 2003-04-14 2004-04-14 Nucleotide vaccine composition
AT04727465T ATE514433T1 (de) 2003-04-14 2004-04-14 Nucleotid und zelluläre vakzine-zusammensetzung
PCT/SE2004/000589 WO2004089413A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
US16/985,393 US11298398B2 (en) 2003-04-14 2020-08-05 Method of treating a philadelphia chromosome-positive tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Publications (1)

Publication Number Publication Date
SE0301109D0 true SE0301109D0 (sv) 2003-04-14

Family

ID=20291035

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Country Status (9)

Country Link
US (2) US10799553B2 (de)
EP (1) EP1658097B1 (de)
JP (1) JP2006523688A (de)
CN (1) CN1805758B (de)
AT (1) ATE514433T1 (de)
AU (1) AU2004227821A1 (de)
CA (1) CA2522456A1 (de)
SE (1) SE0301109D0 (de)
WO (1) WO2004089413A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2690968A1 (en) * 2007-06-19 2008-12-24 Coloplast A/S Multi-layered adhesive appliance
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CN102006891B (zh) * 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
US20100330117A1 (en) * 2008-09-26 2010-12-30 Salubrious Pharmaceutical, Llc Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
WO2011109834A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
EP3620185A1 (de) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injizierbare porenbildende hydrogele für materialbasierte zelltherapien
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (de) 2011-04-27 2018-12-26 President and Fellows of Harvard College Zellfreundliche inverse und opake hydrogele zur zelleinkapselung, zur arzneimittel- und proteinabgabe sowie für funktionelle nanopartikeleinkapselung
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CA2861107A1 (en) * 2012-01-13 2013-07-18 President And Fellows Of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
CA2900824A1 (en) * 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
AU2014249150B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
EP4092112A1 (de) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3484448B1 (de) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
CN107375950B (zh) * 2017-08-02 2020-10-09 深圳大学 一种重组Gal-1过敏环境免疫耐受诱导模型及建立方法
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
US12239666B2 (en) 2018-06-19 2025-03-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
WO2020018413A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (de) 2019-09-23 2025-09-10 Harvard College Biomaterialbasierter antigenfreier impfstoff und verwendung davon
CN112048007B (zh) * 2020-09-11 2022-07-12 北京美康基免生物科技有限公司 一种通用型新型冠状病毒疫苗及其制备方法
GB202014920D0 (en) * 2020-09-22 2020-11-04 Unikum Therapeutics Aps Methods for treating cancer and autoimmune and inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000255A1 (en) 1994-06-23 1996-01-04 Raymond Enterprises, Inc. Making lenticular optical systems and apparatus therefor
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
CA2345817C (en) * 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
US6338040B1 (en) * 1999-02-12 2002-01-08 Agren, Inc. Method for delaying the development in pest species of resistance to control techniques, using insurance to encourage correct uses of refuges
AU3755800A (en) 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US7385023B1 (en) * 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
EP1423080A4 (de) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp Verfahren zur behandlung genetisch definierter proliferativer störungen mit hsp90-hemmern
EP1546358A4 (de) 2002-03-22 2006-06-07 Zymogenetics Inc Anti-il-tif-antikörper und verfahren zur verwendung bei entzündung
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004073641A2 (en) * 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution

Also Published As

Publication number Publication date
US10799553B2 (en) 2020-10-13
CN1805758A (zh) 2006-07-19
AU2004227821A1 (en) 2004-10-21
ATE514433T1 (de) 2011-07-15
CA2522456A1 (en) 2004-10-21
WO2004089413A1 (en) 2004-10-21
US20070071722A1 (en) 2007-03-29
US20210077565A1 (en) 2021-03-18
EP1658097A1 (de) 2006-05-24
US11298398B2 (en) 2022-04-12
EP1658097B1 (de) 2011-06-29
CN1805758B (zh) 2012-04-25
JP2006523688A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
ATE514433T1 (de) Nucleotid und zelluläre vakzine-zusammensetzung
DE60324430D1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
ATE500323T1 (de) Subtilisin-variante
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
PE20090731A1 (es) Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
DK1409506T3 (da) Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
PT1240325E (pt) Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
EA201100071A1 (ru) Новые композиции и способы
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
WO2005003315A3 (en) Compositions and methods for peptide-assisted transfection
MX2014005957A (es) Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
WO2006130525A3 (en) Methods for immunotherapy of cancer
DE69927249D1 (de) Induzierendes alphavirengen- expressionssystem
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
WO2006096989A3 (en) Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression